Cancer medicines prince advisor in Delhi
Treatment of cancer is definitely not an easy scoop of
joy, both in terms of pain and expenses. Some of the potential expenses include
physician, clinical trials, home health care, psychotherapy and prescription.
Survival rate of cancer patients has dramatically increased during the past
years as multiple novel anti- cancer agencies were concerned about the negative
financial effects on the patients and society.
In the year 2019, the National Pharmaceutical Pricing
Authority (NPPA), brought 42 non- scheduled cancer drugs under price control. So
far, 57 anti- cancer drugs were already under price control as scheduled
formulations. This was done in accordance to ‘public interest’ as per
provisions of the Para 19 of the drugs (Prices Control) Order, 2013. The 42
non- scheduled anti- cancer medicines restrict the trade margin on the selling
price (MRP) up to 30%. The provision has brought in savings of minimum ₹105 crores
to consumers, reducing nearly 85% of 105 brand MRPs.
The revised order has waved changes in prices of major
medicines like, maximum retail price of chemotherapy injection, permetrexed
(500mg), used to treat lung cancer, came down from ₹22,000 to ₹2,800. Retail
price of another common chemo drug, epirubicin (100mg), costs ₹276.8. The price
of erlotinib tablet costs ₹1,840 for a pack of 10 of 100mg strength, which
earlier costed ₹6,600. Though, this change didn’t get any drug manufacturers or
companies to react or comment on the changes, but patient groups and
organisations are happy.
The aim of various anti- cancer medicine supplier in
Delhi like 3MEDS, is to prioritise
the customer’s health and wellness over price or billing. They function to
eliminate the barrier of finance by providing the medications with reasonable
and affordable prices. Life matters than the behaviour of profit, through the
market of cancer medications.
Comments
Post a Comment